Apollomics, Inc. (NASDAQ:APLM – Get Free Report)’s share price shot up 1% on Thursday . The company traded as high as $6.00 and last traded at $5.95. 5,262 shares were traded during trading, a decline of 95% from the average session volume of 97,842 shares. The stock had previously closed at $5.89.
Apollomics Stock Performance
The company’s 50 day moving average price is $7.03 and its 200-day moving average price is $9.58.
Apollomics Company Profile
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Read More
- Five stocks we like better than Apollomics
- What is the Nikkei 225 index?
- Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
- What is Short Interest? How to Use It
- Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
- How to Profit From Growth Investing
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
